Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism

NCT00872898 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT00872898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00872898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Lead sponsor
Forest Laboratories
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
Not reported
Enrollment
124 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

autism